New GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward long-term growth.
GSK CEO Luke MielsGSK
By Andrew Joseph
July 28, 2026
Europe Correspondent
Andrew Joseph
About half a year into his tenure as GSK’s CEO, Luke Miels is launch | About half a year into his tenure as GSK’s CEO, Luke Miels…
SEC filings reveal how GSK's new CEO Luke Miels lined up the $10.6B Nuvalent buyout to land cancer drug neladalkib ahead of an…
GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge in a move aimed a bolstering its…
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of…
GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday.
Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain
Sweeping job cuts at GSK to fund £400m Cambridge campus
GSK prepares for patent cliff with $2.5B cost-cutting plan
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
Why Is GSK Stock Gaining Tuesday? - GSK (NYSE:GSK)
GSK announces plans to close main research hub in Stevenage
GSK’s first lung cancer approval, a new IPO path and more
GLP-1s and the High Cost of Providing Health Care
